APP下载

Combination therapy using low dose radiation, plasma exchange, and a robust antiviral may induce synergic beneficial interactions for mitigating severe COVID‐19

2021-12-24AbdollahJafarzadehSeyedAliRezaMortazaviMaryamNematiSeyedMohammadJavadMortazavi

Life Research 2021年3期

Abdollah Jafarzadeh, Seyed Ali Reza Mortazavi Maryam Nemati,, Seyed Mohammad Javad Mortazavi

Combination therapy using low dose radiation, plasma exchange, and a robust antiviral may induce synergic beneficial interactions for mitigating severe COVID‐19

Abdollah Jafarzadeh1,2, Seyed Ali Reza Mortazavi3,Maryam Nemati2,4, Seyed Mohammad Javad Mortazavi5*

1Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.2Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.3Medical Physics Research Committee, Medical Physics and Engineering Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.4Department of Hematology and Laboratory Sciences, School of Para-Medicine, Kerman University of Medical Sciences, Kerman, Iran.5Department Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Recent studies confirm that current antiviral drugs are not fully effective on coronaviruses. Our research team introduced the idea of radiotherapy at low doses for coronavirus disease 2019 (COVID-19) in March 2020. This issue later received much attention from many scientists around the world. Low dose radiation therapy exerts modulatory effects in acute inflammation, potentiate the anti-viral immune responses, and can be localized to the organ affected by inflammatory reactions, such as lungs. The findings of the first clinical trial show that low dose radiation therapy is safe, and reveal early promise of efficacy. Moreover, plasma exchange therapy may be a rescue therapy in severe COVID-19 patients, as it can quickly eliminate the cytokines and chemokines from the circulation. Remdesivir was introduced as an anti-virus agent that prevents viral RNA synthesis and coronavirus replication and reduces the viral load. If antiviral therapy is poor, the virus has ample opportunity to mutate and increase its fitness through adaptive mutations. Given this consideration, instead a single treatment, we preferentially recommend a combination therapy using low dose radiation therapy plasma exchange and a robust antiviral agent (not yet available). This review provides a viewpoint concerning the potential synergistic effects of low dose radiation therapy, plasma exchange therapy and robust antiviral agent in severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-infected patients as a more effective strategy for possible treatment of severe COVID-19 patients.

SARS-CoV-2, COVID-19, Low dose radiation, Plasma exchange, Antiviral

Background

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-mediated coronavirus disease 2019 (COVID-19) has currently influenced more than 212 countries and territories so that World Health Organization has declared its outbreak a worldwide pandemic [1]. SARS-CoV2, a single-stranded RNA virus, belongs to the coronavirus family, and it has about 50.0% and 80.0% genetic similarity with Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), respectively [2]. The coronaviruses have four structural proteins, including S (spike), M (membrane), E (envelope), and N (nucleocapsid) proteins. The SARS-CoV-2-linked S protein binds to a human cell receptor, angiotensin-converting enzyme 2 (ACE2), but it binds more strongly (10–20 fold) than that of SARS-CoV [3,4]. The ACE2 molecule is expressed in a low subgroup of lung cells, namely, type 2 alveolar cells [5]. SARS-CoV-2 can also use alternative receptors or other cellular entry mechanisms, such as antibody-dependent enhancement [5]. The ACE2 expression has been also reported by the epithelial cells of the lung, intestine, heart, kidney, and blood vessels [6,7].Coronaviruses can attack peripheral nerves and enter the central nervous system through the synaptic pathways [8]. Furthermore, the ACE2 expression has also been reported in the central nervous system vascular endothelial cells that provide a direct route for entering SARS-CoV-2into the brain [9]. The central nervous system infection with SARS-CoV-2 can result in respiratory abnormalities in COVID-19 patients[9,10]. Some symptoms such as loss of taste and smell, convulsions and ataxia can be related to neurological impairments in COVID‐19 patients [8]. SARS-CoV-2 is mainly distributed via small droplets discharged from the mouth and nose of an infected person during coughing or sneezing [11]. The COVID-19 manifestations appear after an incubation stage of approximately 5.2 days with a range of 2–14 days. The duration from the emergence of the symptoms of COVID-19 to possible death ranged from 6–41 days with 14 days in median time. As SARS-CoV and MERS-CoV infections, the COVID-19 patients show clinical symptoms, such as nonproductive cough, dyspnea, fever, fatigue, myalgia, and pneumonia[12,13]. The lymphopenia and higher neutrophil-lymphocyte-ratiohave also occurred in severe cases of COVID-19 [14].

Clinically, three forms of COVID-19 include mild infection (80.0%) that exhibits minor and non-specific signs that do not progress to more severe disease, moderate infection (15.0%) display localized inflammation, pneumonia with or without hypoxia, and severe infection (5.0%) exhibit systemic hyperinflammation and acute respiratory distress syndrome (ARDS) with the risk of fatal outcome in critical cases (1–2%) [15].

The entry of SARS-CoV-2 induces apoptosis and necrosis in epithelial and endothelial infected cells leading to lung damage and the release of many types of pro-inflammatory cytokines and numerous driving the massive leukocyte recruitment within the lungs [15]. Patients infected with large viral loads and long periods of virus shedding in their nasopharyngeal secretions are at greater risk to develop severe forms of COVID-19 [16]. Early massive virus replication, extensive apoptosis and necrosis of the lung-related epithelial- and endothelial cells, vascular leakage, releasing of the pro-inflammatory mediators, downregulation of ACE2, failure of the renin-angiotensin system, hyper-inflammatory responses and cytokine storm perform crucial roles in the COVID-19 pathogenesis [15,17]. While the Delta variant (B.1.617.2) is becoming dominant throughout the world, currently available vaccines may fail to fully protect people from new variants[18].

Why do we need a combination therapy?

As highlighted recently by Helmi et al. the antivirals which are available currently are ineffective and the family of coronaviruses is not susceptible to these antivirals at ordinary concentrations that can be used in vivo[19]. Therefore, scientists have tried to use different combinations of the available treatment methods for infections generated by SARS-CoV-2[20]. The modulatory effects of low dose radiation (LDR) on the production of the proinflammatory cytokines and chemokines were also demonstrated[21,22]. In addition, plasma exchange therapy (PET) that is based on removing a patient’s blood plasma and replacing it with an albumin solution or fresh frozen plasma can be used. PET can eliminate the cytokines and chemokines; hence it may exclude the cytokine storm-related to severe forms of COVID-19 [23]. Furthermore, the antiviral remdesivir has been used to decreases the load of SARS-CoV-2 by preventing the replication of the virus[24]. Now, we know that if antiviral therapy is poor, the virus has ample opportunity to mutate and increase its fitness through adaptive mutations. Thus in this paper, instead of focusing on a single treatment, we recommend a combination therapy using low-dose radiation therapy (LDRT), plasma exchange and a robust antiviral agent. Unfortunately, such a robust antiviral agent is not yet available. This review provides a viewpoint concerning the potential synergistic effects of LDRT, PET and a robust antiviral in SARS-CoV-2-infected patients as a more effective strategy for possible treatment of severe COVID-19 patients.

LDR can modulate inflammatory responses

Using radiation therapy for viral pneumonia dates back to 1946 [25]. However, for the first time, Ghadimi-Moghadam et al. modified this treatment for COVID-19 linked pneumonia [26]. Subsequently,this challenging treatment method was proposed by scientists from different countries[27,28]. It has been reported that LDR reduces the mortality rate in patients with bacterial and viral-mediated pneumonia[26,29].Moreover, LDR exerts modulatory effects in acute inflammation via influencing the leukocytes, macrophages, endothelial cells and fibroblasts, as well as the production of cytokines and chemokines [29]. The modulatory effects of low-dose ionizing radiation on the production of the proinflammatory cytokines and chemokines were also demonstrated [21,22]. It has been also reported that high dose radiation downregulates the expression of costimulatory molecules such as a cluster of differentiation(CD) 86 and CD80 on human dendritic cellsand reduces their capacity to present antigen to specific T cells[30]. In contrast to most therapeutic strategies which exert a systemic effect, radiation primarily focuses on the local treatment region, with direct effects on the organ affected by inflammatory reactions, such as the respiratory system. LDR may do not reduce the viral replication directly, but it may promote the anti-viral immune responses including the natural killercells, natural killer T cells, γδ T cells, and CD8+Tcells and interferon(IFN)-γ) production[31,32]. It has been proposed that LDR can have beneficial effects on the alleviation of the COVID-19 through modulation of the immune and inflammatory responses [27]. It has been proposed that doses < 100 centigray(cGy)could be beneficial for COVID-19 treatment. However, some considerations and challenges and recommendations have been raised concerning the LDR[33,34]. As highlighted by Mortazavi et al. [35–37], the advantages of LDRT are not limited to anti-inflammatory responses or preventing thrombosis. Rodel et al. in their recent paper state “SARS-COV‑2 is an RNA virus with an expected moderate to high mutation rate similar to other SARS RNA viruses and usually higher than the corresponding rate of the human host cells. In addition, as discussed in a recent manuscript, any antiviral drug treatment against SARS-CoV‑2 would probably result in a more intense selective pressure on the virus[38].”

Plasma exchange therapy can resolve cytokine storm

Sudden and rapid progression of clinical worsening is usually reported in the late stages (around 7–10 days) of COVID-19, which is related to the occurrence of cytokine storms [15]. The cytokine storm applies to the excessive production of inflammatory cytokines and chemokines with vast broad biological properties[39]. Cytokine storm has been considered as the main reason for the multiple organ failure in severe COVID-19 patients[40]. The use of strategies for the effective exclusion of cytokine storms is vital to prevent the worsening of COVID-19 [39]. Various approaches such as anti‐viral drugs, corticosteroids, immunomodulators are often used to resolve cytokine storms. However, there is not enough clinical evidence that corticosteroid therapy is beneficial to COVID‐19 [40].

PET is useful for cytokine storms and is frequently used for the treatment of some severe and critical patients, such as H1N1 influenza virus-related pneumonia and respiratory failure [41]. PET exerts quick effects on the cytokine storm[42].

PET may be a rescue therapy in severe COVID‐19 patients with cytokine storm and ARDS as an effective and fast method for removing the abnormally raised pro-inflammatory elements, improving the coagulation system and correcting immune disorders [23]. PET has been suggested as a potential supportive therapy for severe forms of COVID-19 and has been reported to be beneficial in some case reports [43]. A report shows that PET was successful in improving the oxygenation index, decreasing the C-reactive proteinlevel and interleukin-6, and restoring the neutrophil-lymphocyte-ratioin three COVID-19 patients with severe ARDS[45]. Moreover, PET in severeCOVID-19patients was associated with improved outcomes, as it has been indicated that PET-treated COVID-19 exhibit a lower mortality rate at 4 days, 28 days compared to patients without PET [23]. Although PET may have promising beneficial effects in severe COVID-19 patients, some considerations have been raised concerning the PET. For example, PET removes inflammatory cytokines along with other plasma proteins and immunoglobulins that may attenuate the immune system [46]. Accordingly, selective removal of harmful pro-inflammatory cytokines using hemoperfusion and perhaps artificial liver blood purification may be considered [39,46]. It has been reported that H1N1 influenza A virus-mediated ARDS has been successfully treated with hemoperfusion and this approach may be useful in the COVID-19 treatment as well [46,47].

Remdesivir interfere with blood viremia and virus spreading

The antiviral remdesivir (a Gilead production) is not approved by the US FDA to treat or prevent any diseases, including COVID-19. However, the emergency use authorization allows remdesivir, to be distributed and used by authorized health care providers to treat hospitalized patients with severe COVID-9. Regarding viral infections, studies conducted over the past decade show that ineffective treatments can lead to viral genome replicates and the existence of selective pressure may drive the SARS-CoV-2 virus to fast adaptation and eventually resistance[48]. Given this consideration, LDRT does not exert any selective pressure on the virus and hence is not capable of leading the virus to evolution through viral mutations, antiviral drugs increase the risk of rare but favorable mutations “coronaviruses have genetic proofreading mechanisms (Sevajol et al., 2014; Smith et al., 2013), and SARS-CoV-2 sequence diversity is very low (Fauver et al., 2020). Still, natural selection can act upon rare but favorable mutations[49].”

In mild and moderate COVID-19 infections, a local potent interferon response characterized by the powerful IFN-stimulated gene expression in patients’ bronchoalveolar lavage fluidis reported [15]. In these infections, effective early IFN response in the lungs can control the infection and provide an opportunity for proper activation of specific immune responses. However, when the viral load is high and the early IFN response fails to control the infection, the virus spreads and enters the blood from the lungs leading to blood viremia and then attacks ACE2-expressing organs, such as kidney and intestine. As above mentioned, coronavirus-associated severe pneumonia is usually related to the quick virus replication, extensive accumulation of inflammatory cells, and elevated production of inflammatory mediators contributing to ALI and ARDS[50,51].

Remdesivir as an adenosine triphosphate nucleoside analog interferes with viral RNA-dependent RNA polymerase thus evading the proofreading by a viral exonuclease and preventing RNA synthesis[52]. It has been reported that remdesivir can potently inhibit SARS-CoV-1 and MERS-CoV replication in several in vitro systems, using primary human airway epithelial cells through suppressing the viral RNA synthesis[24]. Remdesivir also exerts effective protective effects against MERS-CoV and SARS-CoV-1 in animal models [53–55]. Similarly, treatment of the SARS-CoV-2-infected rhesus macaques with remdesivir reduces the lung viral loads and pneumonia but has no effect on the virus shedding [56]. Thus the timely and adequate initial administration of the remdesivir may be effective for treating SARS-CoV-2 infection [7]. Remdesivir can interfere with SARS-CoV-2 propagation in lungs, blood and infected organs. In order to evaluate the safety and efficacy of Remdesivir in COVID-19 patients, several clinical trials have been started. The results from a double-blind controlled trial showed that remdesivir exhibit faster time to clinical improvement in severe COVID-19 patients compared to placebo, although no significant difference was found [24]. The results from a case report study also showed that the remdesivir intravenous infusion to a COVID-19 patient improves clinical symptoms without adverse events[57].

Conclusion

The efficacy of treatment methods such asLDRT[58,59], PETand effective antiviral agents[60] in the management of COVID-19 patients have been previously confirmed by different researchers. Here, we have provided evidence that combination therapy using LDRT, PET and a robust antiviral agent may confer promising beneficial therapeutic effects in severe and critical COVID-19 patients. The proposed combination therapy needs standardization concerning timing, dosing, programming, safety and patient criteria (such as age, gender, pregnancy, and comorbidities).

1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic.. 2020;91(1):157–160.Available: 10.23750/abm.v91i1.9397; https://doi.org/10.23750/abm.v91i1.9397

2. Rabaan AA, Al-Ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview.. 2020;28(2):174–184.

3. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19.. 2020;10(2):102–108. Available: 10.1016/j.jpha.2020.03.001; https://doi.org/10.1016/j.jpha.2020.03.001

4. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.. 2020;7(1):11. Available: 10.1186/s40779-020-00240-0; https://doi.org/10.1186/s40779-020-00240-0

5. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.. 2020;38(1):1–9.Available: 10.1186/10.12932/ap-200220-0772; https://doi.org/10.12932/ap-200220-0772

6. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa..2020;12(1):8.Available: 10.1038/s41368-020-0074-x; https://doi.org/10.1038/s41368-020-0074-x

7. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science.. 2020;52(6):910–941.Available: j.immuni.2020.05.002; https://doi.org/j.immuni.2020.05.002

8. Vellingiri B, Jayaramayya K, Iyer M, et al. COVID-19: a promising cure for the global panic.. 2020;725:138277.Available: 10.1016/j.scitotenv.2020.138277; https://doi.org/10.1016/j.scitotenv.2020.138277

9. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms.. 2020;11(7):995–998. Available: 10.1021/acschemneuro.0c00122; https://doi.org/10.1021/acschemneuro.0c00122

10. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.. 2020;92(6):552–555. Available: 10.1002/jmv.25728; https://doi.org/10.1002/jmv.25728

11. Hussain A, Kaler J, Tabrez E, Tabrez S, Tabrez SSM. Novel COVID-19: acomprehensive review of transmission, manifestation, and pathogenesis.. 2020;12(5):e8184. Available: 10.7759/cureus.8184; https://doi.org/10.7759/cureus.8184

12. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.. 2020;109:102433. Available: 10.1016/j.jaut.2020.102433; https://doi.org/10.1016/j.jaut.2020.102433

13. Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?. 2020;38(2):337–342. https://pubmed.ncbi.nlm.nih.gov/32202240/

14. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China.. 2020;71(15):762–768. Available: 10.1093/cid/ciaa248; https://doi.org/10.1093/cid/ciaa248

15. Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.. 2020;19(7):102567. Available: 10.1016/j.autrev.2020.102567; https://doi.org/10.1016/j.autrev.2020.102567

16. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19.2020;20(6):656–657.Available: 10.1016/S1473-3099(20)30232-2; https://doi.org/10.1016/S1473-3099(20)30232-2

17. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools.. 2020;35(3):266–271. Available: 10.1007/s12250-020-00207-4; https://doi.org/10.1007/s12250-020-00207-4

18. Mlcochova P, Kemp S, Dhar MS, et al. SARS-CoV-2 B. 1.617. 2 Delta variant emergence and vaccine breakthrough. 2021.Available: 10.1021/acschemneuro.0c00122; https://doi.org/10.21203/rs.3.rs-637724/v1

19. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J Clin Med. 2020;9(4):1225. Available: 10.3390/jcm9041225; https://doi.org/10.3390/jcm9041225

20. Zylka-Menhorn V, Grunert G. Coronavirus 2019-nCoV: Der Steckbrief des Virus ist im Fluss.2020;117(6):A-250/B-219/C-215. https://www.aerzteblatt.de/archiv/212365/Coronavirus-2019-nCoV-Der-Steckbrief-des-Virus-ist-im-Fluss

21. Schroder S, Kriesen S, Paape D, Hildebrandt G, Manda K. Modulation of inflammatory reactions by low-dose ionizing radiation: cytokine release of murine endothelial cells is dependent on culture conditions.. 2018;2018:2856518. Available: 10.1155/2018/2856518; https://doi.org/10.1155/2018/2856518

22. Rodel F, Frey B, Manda K, et al. Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation. F. 2012;2:120. Available: 10.3389/fonc.2012.00120; https://doi.org/10.3389/fonc.2012.00120

23. Khamis F, Al-Zakwani I, Al Hashmi S, et al. Therapeutic plasma exchange in adults with severe COVID-19 infection.. 2020;99:214–218. Available: 10.1016/j.ijid.2020.06.064; https://doi.org/10.1016/j.ijid.2020.06.064

24. Sisay M. Available evidence and ongoing clinical trials of remdesivir: could it be a promising therapeutic option for COVID-19?. 2020 May 26;11:791. Available: 10.3389/fphar.2020.00791; https://doi.org/10.3389/fphar.2020.00791

25. Dubin IN, Baylin GJ, Gobble WG, Jr. The effect of roentgen therapy on experimental virus pneumonia; on pneumonia produced in white mice by swine influenza virus.. 1946;55:478–481.

26. Ghadimi-Moghadam A, Haghani M, Bevelacqua JJ, Kaveh-Ahangar A, Mortazavi SMJ, Mortazavi SAR. COVID-19 tragic pandemic: concerns over unintentional “directed accelerated evolution” of novel coronavirus (SARS-CoV-2) and introducing a modified treatment method for ARDS.. 2020;10(2):241–246. Available: 10.31661/jbpe.v0i0.2003-1085; https://doi.org/10.31661/jbpe.v0i0.2003-1085

27. Kirkby C, Mackenzie M. Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?. 2020;147:221.Available: 10.1016/j.radonc.2020.04.004; https://doi.org/10.1016/j.radonc.2020.04.004

28. Lara PC, Burgos J, Macias D. Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment.. 2020;23:27–29. Available: 10.1016/j.ctro.2020.04.006; https://doi.org/10.1016/j.ctro.2020.04.006

29. Rodel F, Arenas M, Ott OJ, et al. Low-dose radiation therapy for COVID-19 pneumopathy: what is the evidence?. 2020 Aug;196(8):679–682. Available: 0.1007/s00066-020-01635-7; https://doi.org/10.1007/s00066-020-01635-7

30. Manda K, Glasow A, Paape D, Hildebrandt G. Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic and T cells.. 2012;2:102. Available: 10.3389/fonc.2012.00102; https://doi.org/10.3389/fonc.2012.00102

31. Yang G, Kong Q, Wang G, et al. Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy.. 2014;29(10):428–434.. Available: 10.1089/cbr.2014.1702; https://doi.org/10.1089/cbr.2014.1702

32. Hekim N, Cetin Z, Nikitaki Z, Cort A, Saygili EI. Radiation triggering immune response and inflammation.. 2015;368(2):156–163.Available: 10.1089/cbr.2014.1702; https://doi.org/10.1016/j.canlet.2015.04.016.

33. Kefayat A, Ghahremani F. Low dose radiation therapy for COVID-19 pneumonia: a double-edged sword.. 2020;147:224–225.Available: 10.1016/j.radonc.2020.04.026; https://doi.org/10.1016/j.radonc.2020.04.026

34. Dhawan G, Kapoor R, Dhawan R, et al. Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS).. 2020;147:212–216. Available: 10.1016/j.radonc.2020.05.002; https://doi.org/10.1016/j.radonc.2020.05.002

35. Mortazavi SMJ, Kefayat A, Cai J. Low dose radiation as a treatment for COVID-19 pneumonia: a threat or real opportunity?. 2020;47(9):3773–3776. Available: 10.1002/mp.14367; https://doi.org/10.1002/mp.14367

36. Mehdizadeh AR, Bevelacqua JJ, Mortazavi SAR, Mortazavi SMJ. COVID-19: Introducing low dose radiation as an effective treatment for pneumonia that shouldn’t induce selective pressure and new mutations. JBiomedPhysEng. 2020;10(3):247–250. Available: 10.31661/jbpe.v0i0.2005-1114; https://doi.org/10.31661/jbpe.v0i0.2005-1114

37. Bevelacqua JJ, Mortazavi SAR, Mortazavi SMJ. Re: Low dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence? Int. 2020;96(10):1236–1237. Available: 10.1080/09553002.2020.1797213; https://doi.org/10.1080/09553002.2020.1797213

38. Rödel F, Arenas M, Ott OJ, et al. Low-dose radiation therapy for COVID-19 pneumopathy: what is the evidence?. 2020;196(8):679–682. Available: 10.1007/s00066-020-01635-7; https://doi.org/10.1007/s00066-020-01635-7

39. Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by SARS-CoV-2.. 2020;509:280–287. Available: 10.1016/j.cca.2020.06.017; https://doi.org/10.1016/j.cca.2020.06.017

40. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.. 2020;395(10223):473–475. Available: 10.1016/s0140-6736(20)30317-2; https://doi.org/10.1016/s0140-6736(20)30317-2

41. Patel P, Nandwani V, Vanchiere J, Conrad SA, Scott LK. Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A--an associated respiratory failure and hemodynamic shock. Pediatr Crit Care Me. 2011;12(2):e87–89. Available: 10.1097/PCC.0b013e3181e2a569; https://doi.org/10.1097/PCC.0b013e3181e2a569

42. Hadem J, Hafer C, Schneider AS, et al. Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-centre study of 23 patients.. 2014;14:24. Available: 10.1186/1471-2253-14-24; https://doi.org/10.1186/1471-2253-14-24

43. Shi H, Zhou C, He P, et al. Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19.. 2020;56(2):105974. Available: 10.1016/j.ijantimicag.2020.105974; https://doi.org/10.1016/j.ijantimicag.2020.105974

44. Luo S, Yang L, Wang C, Liu C, Li D. Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab. J. 2020;49(2):227–231.Available: 10.3785/j.issn.1008-9292.2020.03.06; https://doi.org/10.3785/j.issn.1008-9292.2020.03.06

45. Esmaeili Vardanjani A, Moayedi S, Golitaleb M. COVID-19 pandemic hemoperfusion therapy versus plasma exchange therapy in intensive care.. 2020;19(S1):7–9. Available: 10.18502/ijaai.v19i(s1.r1).2848; https://doi.org/10.18502/ijaai.v19i(s1.r1).2848

46. Takeda S, Munakata R, Abe S, et al. Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion.. 2010;36(5):906–907. Available: 10.1007/s00134-010-1830-8; https://doi.org/10.1007/s00134-010-1830-8

47. Irwin KK, Renzette N, Kowalik TF, Jensen JD. Antiviral drug resistance as an adaptive process.. 2016;2(1):vew014. Available: 10.1093/ve/vew014; https://doi.org/10.1093/ve/vew014

48. Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus.. 2020;182(4):812–827.e19.Available: 10.1016/j.cell.2020.06.043; https://doi.org/10.1016/j.cell.2020.06.043

49. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.2017;39(5):529–539. Available: 10.1007/s00281-017-0629-x; https://doi.org/10.1007/s00281-017-0629-x

50. D'Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the “cytokine storm” for therapeutic benefit.. 2013;20(3):319–327. Available: 10.1128/cvi.00636-12; https://doi.org/10.1128/cvi.00636-12

51. Pandey A, Nikam AN, Shreya AB, et al. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.. 2020;256:117883. Available: 10.1016/j.lfs.2020.117883; https://doi.org/10.1016/j.lfs.2020.117883

52. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.. 2020;11(1):222. Available: 10.1126/scitranslmed.aal3653; https://doi.org/10.1126/scitranslmed.aal3653

53. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.. 2017;9(396):eaal3653. Available: 10.1038/s41467-019-13940-6; https://doi.org/10.1038/s41467-019-13940-6

54. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.. 2020;117(12):6771–6776. Available: 10.1073/pnas.1922083117; https://doi.org/10.1073/pnas.1922083117

55. Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.. 2020;585(7824):273–276. Available: 10.1038/s41586-020-2423-5; https://doi.org/10.1038/s41586-020-2423-5

56. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States.. 2020;382(10):929–936. Available: 10.1056/NEJMoa2001191; https://doi.org/10.1056/NEJMoa2001191

57. Hess CB, Buchwald ZS, Stokes W, et al. Low-dose whole-lung radiation for COVID-19 pneumonia.. 2020;126(23):5109–5113. Available: 10.1002/cncr.33130; https://doi.org/10.1002/cncr.33130

58. Ameri A, Ameri P, Rahnama N, et al. Low-dose whole-lung irradiation for COVID-19 pneumonia: what is the optimal dose? Final results of a pilot study.. 2021;109(4):859–866. Available: 10.1016/j.ijrobp.2020.11.065; https://doi.org/10.1016/j.ijrobp.2020.11.065

59. Putter JS, Seghatchian J. An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research.. 2020;59(5):102934. Available: 10.1016/j.transci.2020.102934; https://doi.org/10.1016/j.transci.2020.102934

60. Yousefi H, Mashouri L, Okpechi SC, Alahari N, Alahari SK. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: a review describing drug mechanisms of action.. 2021;183:114296. Available: 10.1016/j.bcp.2020.114296; https://doi.org/10.1016/j.bcp.2020.114296

thanks Robert Jeyasingh Samuel Pushparaj, Taj Malook Khanand other anonymous reviewers for their contribution to the peer review of this paper.

:

SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; COVID-19, coronavirus disease 2019; MERS-CoV, Middle East respiratory syndrome coronavirus; SARS-CoV, severe acute respiratory syndrome coronavirus; ACE2, angiotensin-converting enzyme 2; ARDS, acute respiratory distress syndrome; LDR, low dose radiation; LDRT, low-dose radiation therapy; PET, plasma exchange therapy; CD, cluster of differentiation.

:

The authors declare that they have no conflict of interest.

:

Jafarzadeh A, Mortazavi SAR, Nemati M, Mortazavi SMJ. Combination therapy using low dose radiation, plasma exchange, and a robust antiviral may induce synergic beneficial interactions for mitigating severe COVID‐19.. 2021;4(3):25. doi: 10.53388/life2021-0524-308.

:Shan-Shan Lin.

:24 May 2021,

10 July 2021,

: 25 July 2021

© 2021 By Authors. Published by TMR Publishing Group Limited. This is an open access article under the CC-BY license (http://creativecommons.org/licenses/BY/4.0/).

Seyed Mohammad Javad Mortazavi. Department Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail: mortazavismj@gmail.com. ORCID iD: 0000-0003-0139-2774.


登录APP查看全文